Singapore - English - HSA (Health Sciences Authority)

implantex pte. ltd. - cardiovascular - the myval transcatheter heart valve (thv) and accessories are indicated for relief of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis as judged by a heart team (including a cardiac surgeon) and in patients who are at high risk for open heart surgical therapy (society of thoracic surgeons operative risk score of ≥4% or at a ≥15% risk of mortality at 30 days).

Singapore - English - HSA (Health Sciences Authority)

implantex pte. ltd. - neurology - the envi™-sr is intended for use to restore blood flow in the neurovasculature by removing thrombus in patients experiencing ischemic stroke within 8 hours of symptom onset. patients who are ineligible for iv tpa or who fail iv tpa therapy are candidates for treatment.

Singapore - English - HSA (Health Sciences Authority)

implantex pte. ltd. - cardiovascular - intended use: • restoring atherosclerotic lesions of the common and external iliac arteries and the renal arteries. • treatment of aneurysms and perforations, ruptures and acute fistulas. indications: patients presenting peripheral vascular system pathologies.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - allopurinol 100mg - tablet - 100 mg - active: allopurinol 100mg excipient: lactose monohydrate magnesium stearate maize starch povidone - · allopurinol is mainly used in the management of primary gout or secondary hyperuricaemia associated with chronic gout. it is not, however, used to treat an acute attack of gout as it has no analgesic, antiinflammatory or uricosuric activity and may prolong the attack. if changing therapy from a uricosuric agent alone, the dose should be reduced gradually while allopurinol is introduced. in severe cases of chronic gout, allopurinol can be used together with a uricosuric agent unless the latter is contra-indicated.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - allopurinol 300mg - tablet - 300 mg - active: allopurinol 300mg excipient: lactose monohydrate magnesium stearate maize starch povidone

New Zealand - English - Medsafe (Medicines Safety Authority)

origen pharmaceuticals limited - amitriptyline hydrochloride;  ;   - tablet - 10mg, 25mg, 50mg - active: amitriptyline hydrochloride    

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - doxepin hydrochloride 11.31mg equivalent to doxepin 10.00 mg (granulated);  ; doxepin hydrochloride 11.31mg equivalent to doxepin 10.00 mg (granulated) - capsule - 10 mg - active: doxepin hydrochloride 11.31mg equivalent to doxepin 10.00 mg (granulated)   excipient: colloidal silicon dioxide fea blue op   gelatin lactose monohydrate magnesium stearate maize starch active: doxepin hydrochloride 11.31mg equivalent to doxepin 10.00 mg (granulated) excipient: brilliant blue fcf colloidal silicon dioxide erythrosine gelatin   iron oxide red iron oxide yellow lactose monohydrate magnesium stearate maize starch titanium dioxide  

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - doxepin hydrochloride 28.27mg (granulated. = doxepin 25 mg);  ; doxepin hydrochloride 28.27mg (granulated. = doxepin 25 mg) - capsule - 25 mg - active: doxepin hydrochloride 28.27mg (granulated. = doxepin 25 mg)   excipient: colloidal silicon dioxide fed flesh op   gelatin lactose monohydrate magnesium stearate maize starch active: doxepin hydrochloride 28.27mg (granulated. = doxepin 25 mg) excipient: colloidal silicon dioxide erythrosine gelatin   iron oxide red   lactose monohydrate magnesium stearate maize starch titanium dioxide  

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - doxepin hydrochloride 56.54mg (granulated. = doxepin 50 mg);  ; doxepin hydrochloride 56.54mg (granulated. = doxepin 50 mg) - capsule - 50 mg - active: doxepin hydrochloride 56.54mg (granulated. = doxepin 50 mg)   excipient: colloidal silicon dioxide fea scarlet op   gelatin lactose monohydrate magnesium stearate maize starch active: doxepin hydrochloride 56.54mg (granulated. = doxepin 50 mg) excipient: colloidal silicon dioxide erythrosine gelatin   iron oxide yellow lactose monohydrate magnesium stearate maize starch sunset yellow fcf titanium dioxide   - symptoms of depressive illness, especially where sedation is required. doxepin may be used with benefit where symptoms are of short or long duration prior to treatment and in patients with a wide range of intensity of illness. as with other psychotherapeutic agents, the degree of response varies with each patient. in patients exhibiting a beneficial response, this may be seen within a few days of commencing therapy, while others may not respond for two weeks or longer. due to its excellent toleration, doxepin is particularly useful in ambulatory patients seen in general practice as well as in the treatment of hospitalised patients.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - doxepin hydrochloride 84.81mg (granulated. = doxepin 75 mg);   - capsule - 75 mg - active: doxepin hydrochloride 84.81mg (granulated. = doxepin 75 mg)   excipient: colloidal silicon dioxide fea blue op   gelatin lactose monohydrate magnesium stearate maize starch